Designing Early-Phase Clinical Trials for Cell and Gene Therapy Products
Early-phase clinical trials for cell and gene therapy (CGT) products differ from those for other pharmaceuticals due to unique product features and previous clinical experiences, which have revealed substantial risks, including multi-organ failure, leukemia, and tumor development. Factors such as prolonged biological activity, immunogenicity, and invasive administration procedures contribute to these risks. The design of […]
Designing Early-Phase Clinical Trials for Cell and Gene Therapy Products Read More »